CEL-SCI Corporation (CVM)
NYSEAMERICAN: CVM · Real-Time Price · USD
6.45
+0.16 (2.54%)
Dec 5, 2025, 4:00 PM EST - Market closed
CEL-SCI Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
44
Market Cap
51.70M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
CVM News
- 6 weeks ago - CEL-SCI Presentation at LD Micro "Main Event" Available on Tuesday, October 21, 2025 - Newsfile Corp
- 2 months ago - CEL-SCI Corporation to Present at LD Micro "Main Event" Investor Conference - Newsfile Corp
- 3 months ago - CEL-SCI Announces Closing of $10 Million Public Offering - Business Wire
- 3 months ago - CEL-SCI Announces Pricing of $10 Million Public Offering - Business Wire
- 3 months ago - CEL-SCI Announces Proposed Public Offering - Business Wire
- 4 months ago - CEL-SCI Reports Fiscal Third Quarter 2025 Financial Results - Business Wire
- 4 months ago - CEL-SCI's Multikine Head and Neck Cancer Immunotherapy Breakthrough Medicine Designation Filed in Saudi Arabia: Allows for Patient Access and Reimbursement/Sale Upon Granting of the Designation Which Takes Approximately 60 Days Based on SFDA Timeline - Business Wire
- 5 months ago - CEL-SCI Announces Closing of $5.7 Million Offering Priced At-The-Market Under NYSE American Rules - Business Wire